Skip to main content

2024 Editor's Highlights

As Editor-in-Chief and Deputy Editor of Cardiovascular Diabetology, we would like to thank all our Associate Editors for their invaluable contributions during 2024. Their dedication to maintaining the high standards of the journal is truly commendable.

The rigorous review process and insightful comments they provide have significantly improved the quality of the papers published. Their expertise and time commitment are essential to the success of the journal. We also thank the editors who have suggested topics for collections or stand-alone articles, and those who have published manuscripts from their own research group.

During this year, the journal's team has been enriched with the addition of a Deputy Editor, a Social Media Editor and various new Associate Editors. Along with Victoria and Springer Nature, one of the innovations we implemented this year has been the introduction of an annual award for the most distinguished Associate Editors. This year the award was given to the Editors who more solidly based their recommendations, whether for acceptance or rejection. In addition, we want to extend our gratitude to the external reviewers, whose detailed evaluations and valuable feedback have also played a crucial role in maintaining the quality and integrity of the journal.

Looking ahead to 2025, we aim to further expand the journal’s reach by encouraging submissions that address emerging challenges in the diabetes-cardiovascular field and its interplay with metabolic abnormalities. In the future, Cardiovascular Diabetology may also consider the implementation of additional awards, related to other deeds, achievements or categories.

An additional relevant innovation is that since this year we have encouraged authors of original articles and reviews to include a Research Insights summary and a Graphical Abstract to condense the key findings of their work. Research Insights represent a structured mini-abstract, while the graph provides a useful visual outline of the article. These features are currently optional but will likely become an integral part of the submission process soon.

We would like to highlight that this year our journal has published 445 articles, the largest number until now, and also the submissions have increased enormously – more than 50%. The thematic preferences have been like those of the previous biennium; the three leading topics – quantity ordered - were directly or indirectly related to heart failure, obesity and biomarkers. Nevertheless, the journal has also published significant studies in emerging fields, highlighting its commitment to promoting a diverse and integrative approach to cardiovascular and metabolic research.

Regarding the citation indexes, Cardiovascular Diabetology’s current 2-year Journal Impact Factor (JIF) is 8.5, less than last year. On the other hand, the journal is ranked by JIF in the very prestigious 93.4 (15 out of 220) and 94.4 (11 out of 186) percentiles of academic publications in the categories "Cardiac & Cardiovascular Systems” and “Endocrinology & Metabolism”, respectively. Both indexes are the highest attained by the journal in its entire history. In addition, during 2023 we had over 3 million accesses to CVDB articles, over 2,5 million full-text downloads and more than 3,000 Altmetric mentions. While this achievement should not be overhyped, it provides a solid testimony of the visibility and good average quality of the published articles. We hope that these favorable data will continue to attract manuscripts authored by leading basic and clinical scientists from cardiology, angiology, diabetology and their related fields.

Below, we would like to offer you a selection of the 2024 most relevant articles, reflecting both the journal's focus on key areas and its commitment to highlighting broad and high-impact research.

Prof. Enrique Fisman, MD                                               
Dr. Francisco Westermeier, PhD

The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003–2018
Dang, Keke; Wang, Xuanyang; Hu, Jinxia; Zhang, Yuntao; Cheng, Licheng; Qi, Xiang; Liu, Lin; Ming, Zhu; Tao, Xinmiao; Li, Ying

The neutrophil-to-lymphocyte ratio is associated with all-cause and cardiovascular mortality among individuals with hypertension
Zhang, Xuexue; Wei, Rui; Wang, Xujie; Zhang, Wantong; Li, Mengxuan; Ni, Tian; Weng, Weiliang; Li, Qiuyan

Association between the cumulative average triglyceride glucose-body mass index and cardiovascular disease incidence among the middle-aged and older population: a prospective nationwide cohort study in China            
Li, Fadong; Wang, Yue; Shi, Boqun; Sun, Shuaifeng; Wang, Shen; Pang, Shuo; Wu, Xiaofan

The association between TyG and all-cause/non-cardiovascular mortality in general patients with type 2 diabetes mellitus is modified by age: results from the cohort study of NHANES 1999–2018
Yao, Younan; Wang, Bo; Geng, Tian; Chen, Jiyan; Chen, Wan; Li, Liwen

Association between different insulin resistance surrogates and all-cause mortality in patients with coronary heart disease and hypertension: NHANES longitudinal cohort study
Hou, Xin-Zheng; Lv, Yan-Fei; Li, Yu-Shan; Wu, Qian; Lv, Qian-Yu; Yang, Ying-Tian; Li, Lan-Lan; Ye, Xue-Jiao; Yang, Chen-Yan; Wang, Man-Shi; Cao, Lin-Lin; Wang, Shi-Han

Double diabetes—when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition     
Bielka, Weronika; Przezak, Agnieszka; Molęda, Piotr; Pius-Sadowska, Ewa; Machaliński, Bogusław

Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network
García-Vega, David; Sánchez-López, David; Rodríguez-Carnero, Gemma; Villar-Taibo, Rocío; Viñuela, Juan E.; Lestegás-Soto, Adán; Seoane-Blanco, Ana; Moure-González, María; Bravo, Susana B.; Fernández, Ángel L.; González-Juanatey, José R.; Eiras, Sonia

Interacting and joint effects of triglyceride-glucose index (TyG) and body mass index on stroke risk and the mediating role of TyG in middle-aged and older Chinese adults: a nationwide prospective cohort study  
Huo, Rong-Rui; Liao, Qian; Zhai, Lu; You, Xue-Mei; Zuo, Yan-Li

Association between triglyceride-glucose related indices with the all-cause and cause-specific mortality among the population with metabolic syndrome            
Wei, Xiaoyuan; Min, Yu; Song, Ge; Ye, Xin; Liu, Lei

Link between triglyceride-glucose-body mass index and future stroke risk in middle-aged and elderly chinese: a nationwide prospective cohort study   
Shao, Yuankai; Hu, Haofei; Li, Qiming; Cao, Changchun; Liu, Dehong; Han, Yong

Association of the triglyceride-glucose index with all-cause and cardiovascular mortality in patients with cardiometabolic syndrome: a national cohort study               
Liu, Quanjun; Zhang, Yeshen; Chen, Shuhua; Xiang, Hong; Ouyang, Jie; Liu, Huiqin; Zhang, Jing; Chai, Yanfei; Zhan, Zishun; Gao, Peng; Zhang, Xiao; Fan, Jianing; Zheng, Xinru; Zhang, Zhihui; Lu, Hongwei

Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus
Valencia, Inés; Lumpuy-Castillo, Jairo; Magalhaes, Giselle; Sánchez-Ferrer, Carlos F.; Lorenzo, Óscar; Peiró, Concepción

The association between triglyceride glucose-body mass index and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study from MIMIC-IV database
Hu, Yi; Zhao, Yiting; Zhang, Jing; Li, Chaomin

Prognostic implications of systemic immune-inflammation index in myocardial infarction patients with and without diabetes: insights from the NOAFCAMI-SH registry
Luo, Jiachen; Qin, Xiaoming; Zhang, Xingxu; Zhang, Yiwei; Yuan, Fang; Shi, Wentao; Liu, Baoxin; Wei, Yidong

GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
Marfella, Raffaele; Prattichizzo, Francesco; Sardu, Celestino; Rambaldi, Pier Francesco; Fumagalli, Carlo; Marfella, Ludovica Vittoria; La Grotta, Rosalba; Frigé, Chiara; Pellegrini, Valeria; D’Andrea, Davide; Cesaro, Arturo; Calabrò, Paolo; Pizzi, Carmine; Antonicelli, Roberto; Ceriello, Antonio; Mauro, Ciro; Paolisso, Giuseppe

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, Oliver; Barnard-Kelly, Katharine; Battelino, Tadej; Ceriello, Antonio; Larsson, Helena Elding; Fernández-Fernández, Beatriz; Forst, Thomas; Frias, Juan-Pablo; Gavin, James R.; Giorgino, Francesco; Groop, Per-Henrik; Heerspink, Hiddo J. L.; Herzig, Stephan; Hummel, Michael; Huntley, George; Ibrahim, Mahmoud; Itzhak, Baruch; Jacob, Stephan; Ji, Linong; Kosiborod, Mikhail; Lalic, Nebosja; Macieira, Sofia; Malik, Rayaz A.; Mankovsky, Boris; Marx, Nikolaus; Mathieu, Chantal; Müller, Timo D.; Ray, Kausik; Rodbard, Helena W.; Rossing, Peter; Rydén, Lars; Schumm-Draeger, Petra-Maria; Schwarz, Peter; Škrha, Jan; Snoek, Frank; Tacke, Frank; Taylor, Bruce; Jeppesen, Britta Tendal; Tesfaye, Solomon; Topsever, Pinar; Vilsbøll, Tina; Yu, Xuefeng; Standl, Eberhard

Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
Ahmad, Aftab; Sabbour, Hani

The double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, María Teresa; Pérez-Montes de Oca, Alejandra; Julve, Josep; Alonso, Nuria

The role of mitochondrial DNA copy number in cardiometabolic disease: a bidirectional two-sample mendelian randomization study      
Qin, Pei; Qin, Tianhang; Liang, Lei; Li, Xinying; Jiang, Bin; Wang, Xiaojie; Ma, Jianping; Hu, Fulan; Zhang, Ming; Hu, Dongsheng

Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study       
Htoo, Phyo T.; Tesfaye, Helen; Schneeweiss, Sebastian; Wexler, Deborah J.; Everett, Brendan M.; Glynn, Robert J.; Schmedt, Niklas; Koeneman, Lisette; Déruaz-Luyet, Anouk; Paik, Julie M.; Patorno, Elisabetta

Is systemic inflammation a missing link between cardiometabolic index with mortality? Evidence from a large population-based study        
Xu, Bin; Wu, Qian; La, Rui; Lu, Lingchen; Abdu, Fuad A.; Yin, Guoqing; Zhang, Wen; Ding, Wenquan; Ling, Yicheng; He, Zhiyuan; Che, Wenliang

Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes  
Gamez, Monica; Elhegni, Hesham E.; Fawaz, Sarah; Ho, Kwan Ho; Campbell, Neill W.; Copland, David A.; Onions, Karen L.; Butler, Matthew J.; Wasson, Elizabeth J.; Crompton, Michael; Ramnath, Raina D.; Qiu, Yan; Yamaguchi, Yu; Arkill, Kenton P.; Bates, David O.; Turnbull, Jeremy E.; Zubkova, Olga V.; Welsh, Gavin I.; Atan, Denize; Satchell, Simon C.; Foster, Rebecca R.

Data-independent LC-MS/MS analysis of ME/CFS plasma reveals a dysregulated coagulation system, endothelial dysfunction, downregulation of complement machinery
Nunes, Massimo; Vlok, Mare; Proal, Amy; Kell, Douglas B.; Pretorius, Etheresia

Causal associations between insulin and Lp(a) levels in Caucasian population: a Mendelian randomization study
Lejawa, Mateusz; Goławski, Marcin; Fronczek, Martyna; Osadnik, Tadeusz; Paneni, Francesco; Ruscica, Massimiliano; Pawlas, Natalia; Lisik, Małgorzata; Banach, Maciej

Lipoxin A4 improves cardiac remodeling and function in diabetes-associated cardiac dysfunction  
Fu, Ting; Mohan, Muthukumar; Bose, Madhura; Brennan, Eoin P.; Kiriazis, Helen; Deo, Minh; Nowell, Cameron J.; Godson, Catherine; Cooper, Mark E.; Zhao, Peishen; Kemp-Harper, Barbara K.; Woodman, Owen L.; Ritchie, Rebecca H.; Kantharidis, Phillip; Qin, Cheng Xue

Association of plasma proteomics with incident coronary heart disease in individuals with and without type 2 diabetes: results from the population-based KORA study
Luo, Hong; Huemer, Marie-Theres; Petrera, Agnese; Hauck, Stefanie M.; Rathmann, Wolfgang; Herder, Christian; Koenig, Wolfgang; Hoyer, Annika; Peters, Annette; Thorand, Barbara

Acute-to-chronic glycemic ratio as an outcome predictor in ischemic stroke in patients with and without diabetes mellitus     
Climent, Elisenda; Rodriguez-Campello, Ana; Jiménez-Balado, Joan; Fernández-Miró, Mercè; Jiménez-Conde, Jordi; Llauradó, Gemma; Ois, Ángel; Flores, Juana A.; Cuadrado-Godia, Elisa; Steinhauer, Eva Giralt; Chillarón, Juan J.

Sex differences in the diagnostic algorithm of screening for heart failure by symptoms and NT-proBNP in patients with type 2 diabetes             
Hofer-Zeni, Sarah; Leutner, Michael; Klimek, Peter; Bellach, Luise; Pavo, Noemi; Prausmüller, Suriya; Hülsmann, Martin; Kautzky-Willer, Alexandra

The potential anti-arrhythmic effect of SGLT2 inhibitors  
Duan, Hong-Yi; Barajas-Martinez, Hector; Antzelevitch, Charles; Hu, Dan

Evidence that tirzepatide protects against diabetes-related cardiac damages
Taktaz, Fatemeh; Scisciola, Lucia; Fontanella, Rosaria Anna; Pesapane, Ada; Ghosh, Puja; Franzese, Martina; Tortorella, Giovanni; Puocci, Armando; Sommella, Eduardo; Signoriello, Giuseppe; Olivieri, Fabiola; Barbieri, Michelangela; Paolisso, Giuseppe

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice              
Vercalsteren, Ellen; Karampatsi, Dimitra; Buizza, Carolina; Nyström, Thomas; Klein, Thomas; Paul, Gesine; Patrone, Cesare; Darsalia, Vladimer

Gestational diabetes mellitus and development of intergenerational overall and subtypes of cardiovascular diseases: a systematic review and meta-analysis            
Chen, Ashley; Tan, Breanna; Du, Ruochen; Chong, Yap Seng; Zhang, Cuilin; Koh, Angela S.; Li, Ling-Jun

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 8.5
    5-year Journal Impact Factor: 8.9
    Source Normalized Impact per Paper (SNIP): 1.855
    SCImago Journal Rank (SJR): 2.621

    Speed 2024
    Submission to first editorial decision (median days): 1
    Submission to acceptance (median days): 65

    Usage 2024
    Downloads: 3,422,583
    Altmetric mentions: 2,621